We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Desert squibb

22 September 2006 By Robert Cyran

Investors in the US drug group have spent the last ten years wandering in a desert of poor returns. Now a takeover bid beckons. However, a lingering patent dispute and continuing government supervision of Bristol mean any bid is unlikely to emerge before June.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)